Germany
· Delayed Price · Currency is EUR Biotechnology Assets Statistics
Total Valuation
BST:041 has a market cap or net worth of EUR 19.76 million. The enterprise value is 21.32 million.
| Market Cap | 19.76M |
| Enterprise Value | 21.32M |
Important Dates
The last earnings date was Tuesday, April 21, 2026.
| Earnings Date | Apr 21, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 74.29M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 0.09% |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.47 |
| PB Ratio | 3.06 |
| P/TBV Ratio | 4.40 |
| P/FCF Ratio | 35.15 |
| P/OCF Ratio | 34.41 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -10.26 |
| EV / Sales | 6.98 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 37.94 |
Financial Position
The company has a current ratio of 1.02, with a Debt / Equity ratio of 0.34.
| Current Ratio | 1.02 |
| Quick Ratio | 1.02 |
| Debt / Equity | 0.34 |
| Debt / EBITDA | n/a |
| Debt / FCF | 3.88 |
| Interest Coverage | -10.39 |
Financial Efficiency
Return on equity (ROE) is -30.40% and return on invested capital (ROIC) is -21.80%.
| Return on Equity (ROE) | -30.40% |
| Return on Assets (ROA) | -7.67% |
| Return on Invested Capital (ROIC) | -21.80% |
| Return on Capital Employed (ROCE) | -16.88% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 101,771 |
| Profits Per Employee | -69,302 |
| Employee Count | 30 |
| Asset Turnover | 0.21 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -143,517 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -0.82% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -0.82% |
| 50-Day Moving Average | 0.21 |
| 200-Day Moving Average | 0.25 |
| Relative Strength Index (RSI) | 63.34 |
| Average Volume (20 Days) | n/a |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BST:041 had revenue of EUR 3.05 million and -2.08 million in losses.
| Revenue | 3.05M |
| Gross Profit | 2.76M |
| Operating Income | -1.75M |
| Pretax Income | -2.22M |
| Net Income | -2.08M |
| EBITDA | -1.41M |
| EBIT | -1.75M |
| Earnings Per Share (EPS) | n/a |
Balance Sheet
The company has 615,487 in cash and 2.18 million in debt, giving a net cash position of -1.57 million.
| Cash & Cash Equivalents | 615,487 |
| Total Debt | 2.18M |
| Net Cash | -1.57M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 6.45M |
| Book Value Per Share | n/a |
| Working Capital | 50,655 |
Cash Flow
In the last 12 months, operating cash flow was 574,211 and capital expenditures -12,080, giving a free cash flow of 562,131.
| Operating Cash Flow | 574,211 |
| Capital Expenditures | -12,080 |
| Depreciation & Amortization | 338,090 |
| Net Borrowing | -1.22M |
| Free Cash Flow | 562,131 |
| FCF Per Share | n/a |
Margins
Gross margin is 90.45%, with operating and profit margins of -57.27% and -68.10%.
| Gross Margin | 90.45% |
| Operating Margin | -57.27% |
| Pretax Margin | -72.80% |
| Profit Margin | -68.10% |
| EBITDA Margin | -46.20% |
| EBIT Margin | -57.27% |
| FCF Margin | 18.41% |
Dividends & Yields
BST:041 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -10.52% |
| FCF Yield | 2.84% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BST:041 has an Altman Z-Score of -8.64 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -8.64 |
| Piotroski F-Score | 5 |